Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.

Bang ZhengAmelia C A GreenJohn TazareHelen J CurtisLouis FisherLinda NabAnna SchultzeViyaasan MahalingasivamEdward P K ParkerWilliam J HulmeSebastian C J BaconNicholas J DeVitoChristopher BatesDavid EvansPeter InglesbyHenry DrysdaleSimon DavyJonathan CockburnCaroline E MortonGeorge HickmanTom WardRebecca M SmithJohn ParryFrank HesterSam HarperAmir MehrkarRosalind M EggoAlex J WalkerStephen J W EvansIan J DouglasBrian MacKennaBen GoldacreLaurie A Tomlinson

Published in: BMJ (Clinical research ed.) (2022)

In routine care of adult patients in England with covid-19 in the community, at high risk of severe outcomes from covid-19, those who received sotrovimab were at lower risk of severe outcomes of covid-19 than those treated with molnupiravir.

Keyphrases

coronavirus disease
sars cov
healthcare
early onset
mental health
newly diagnosed
end stage renal disease
respiratory syndrome coronavirus
ejection fraction
type diabetes
peritoneal dialysis
adipose tissue
skeletal muscle
metabolic syndrome
drug induced
pain management
patient reported outcomes